To,

Head of Paediatric Medicines
European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision

Actives substances(s): Pimodivir

Invented name: NA

Latest Decision number(s): P/0003/2019

Corresponding PIP number(s): EMEA-001975-PIP01-16-M02

Date of initial marketing authorisation granted: NA

Date of authorisation of new indication, pharmaceutical form or route of administration: NA

Please note that development of the medicinal product above in the following **condition(s)/indication(s)**:

Treatment of influenza

☒ has been discontinued

☐ has been suspended/put on long-term hold (with possible re-start at a later time)

for the following reason(s): (tick all that apply)

☐ (possible) lack of efficacy in adults

☐ (possible) lack of efficacy in children

☐ (possible) unsatisfactory safety profile in adults

☐ (possible) unsatisfactory safety profile in children

☐ commercial reasons (please specify:)

☐ manufacturing / quality problems

☐ other regulatory action (please specify:) (e.g. suspension, revocation of M.A.)

☒ other reason (please specify: Futility in 63623872FLZ3001 which led to discontinuation of the Janssen clinical development program for Pimodivir)

Please add a brief description (max 2000 characters) of the reason(s) for the discontinuation / suspension:

The Applicant Janssen-Cilag International N.V. would like to inform that on 28 Aug 2020, a decision was made to discontinue development of pimodivir (JNJ-63623872). This decision was based on results from a pre-planned interim analysis of the Phase 3 trial 63623872FLZ3001 that found pimodivir in combination with standard of care (SOC) treatment unlikely to demonstrate added benefit in hospitalized patients with influenza A as compared to SOC alone. Due to Janssen's decision to discontinue pimodivir clinical development, the ongoing Phase 3 trial 63623872FLZ3002 and Phase 1 trial 63623872FLZ1014 were also stopped.

Please note that if the PIP has been submitted as part of a marketing authorisation application in order to comply with the requirements of Article 7 of the Paediatric Regulation (as a condition of the validation of the respective application) and a marketing authorisation was granted based on this application, then there is a legal obligation to complete that PIP. The same applies if there has been a successful post-authorisation application, where the PIP was included in order to comply with the requirements of Article 8 of the Paediatric Regulation.

Please confirm if any of the above applies to the PIP in question:

Yes☐ No☒

If yes, it means that based on the Marketing Authorisation obtained at the end of that initial procedure or the successful post-authorisation application, as applicable, you are obliged to complete that PIP. That obligation cannot be cancelled by a unilateral decision, including by withdrawing the MA. Such PIP must be completed, unless it is modified in agreement with the PDCO by removing all outstanding PIP measures or granting a full product-specific waiver instead (upon relevant circumstances in accordance with the Paediatric Regulation). Non-completion of a binding PIP establishes noncompliance with the requirements of the Paediatric Regulation, which the European Medicines Agency has an obligation to report to the European Commission.

Name and signature of the PIP contact point: Signature on file
Date: 10 December 2021

Contact for inquiries from interested parties: Janssen-Cilag International NV
Telephone: +44 (0) 7920 490 411
Email: contact@janssen-emea.com